We read with great interest the nationwide register-based cohort study by Roupe et al., recently published in the European Journal of Internal Medicine [1]. The authors should be commended for addressing a clinically important and comparatively underexplored question—the relative safety of direct oral anticoagulants (DOACs) in older, cancer-free patients with venous thromboembolism (VTE)—using high-quality Swedish national registries. Their findings provide valuable real-world evidence on bleeding risk across both primary and secondary treatment phases.
